Navigation Links
AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

, Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center, at Dana-Farber Cancer Institute (DFCI) in Boston, MA and Dr. Kenneth C, Anderson, Chief, Division of Hematologic Neoplasia at DFCI.

Dr. Richardson's clinical research focuses on studying novel therapies for multiple myeloma. He was the lead investigator of the SUMMIT and APEX clinical trials that led to the FDA approval of bortezomib (Velcade(R)) for the treatment of multiple myeloma. More recently, he served as clinical trials core chair of the Multiple Myeloma Research Consortium, completing 5 years of service in the role this year. Dr. Anderson serves as Chair of the NCCN Multiple Myeloma Clinical Practice Guidelines Committee and chairs the scientific advisory board for the Multiple Myeloma Research Foundation. In addition to playing an integral role in the development and approval of bortezomib (Velcade(R)), Drs. Richardson and Anderson led both preclinical and early phase clinical trials for the immunomodulatory drug lenalidomide (Revlimid(R)), leading to its FDA approval in 2007.

Juergen Engel, Ph.D., President and CEO at AEterna Zentaris stated, "We are very excited with Keryx's initiation of this Phase 3 trial with perifosine, our lead oncology compound. Based on prior positive results, we believe that perifosine could become a novel oral combination treatment of great benefit to patients suffering from multiple myeloma."

About the Phase 3 Trial Design

The Phase 3 trial is a randomized (1:1), double-blind trial comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade(R)) and dexamethasone in approximately 400 patients with relapsed or relapsed/refractory multiple myeloma. Patients will be randomized to bortezomib (Velcade(R)) at 1.3 mg/m2 days 1, 4, 8 and 11 every 21 days in combination with dexamethasone 20 mg on the day of and day after bortezomib (Velcade(R)) treatment, and either pe
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Announces Appointment of New Board Member
2. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
5. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
6. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
7. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
8. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
9. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Rainbow Scientific, Inc. (RSI), ... recently opened an online store to add customer ... lines developed and manufactured by Biological Industries, Inc. ... Biological Industries’ Nutristem® serum-free, xeno-free reagents for human ... cell (hESC) culture. , The online store ...
(Date:9/30/2014)... New Jersey (PRWEB) September 30, 2014 ... it has been chosen by the Parenteral Drug ... (November 18 and 19, 2014) on container closure integrity ... container closure integrity test methods and philosophies detailed in ... – Integrity Evaluation. The course will span ...
(Date:9/29/2014)... 2014 Each year in the ... medical attention. In the military, burn injury is ... battlefield medical care. More than 800 service members ... wounds heal slowly, remain inflamed and often become ... debilitating and functionally damaging. While developments in supportive ...
(Date:9/29/2014)... BEACH, Va. , Sept. 29, 2014 /PRNewswire-USNewswire/ ... from the fields of cartilage repair, regeneration, allograft ... attendees from around the world gathered to discuss ... LifeNet Health Institute of Regenerative Medicine symposium, ... Direction . Topics included Orthopedic Biosurgery, Minced Juvenile ...
Breaking Biology Technology:Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4Faster Healing with Fewer Scars 2World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... BEIJING, Sept. 8 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.,(NYSE Amex: ... China, today announced,that the first lot of PANFLU.1, its H1N1 ... for the Control of Pharmaceutical and,Biological Products and obtained the ... vaccines are ready for delivery. , ...
... SANTA CLARA, Calif., Sept. 8 Cell Biosciences, ... announced that they have entered into a definitive agreement providing ... $1.50 per share or approximately $17.9 million in cash. This ... include a global infrastructure and a broad protein analysis product ...
... LAIYANG, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, Inc. (OTC ... with its principal operations in the People,s,Republic of China, ... The Company expects to meet or exceed its ... income of $40 to $43 million for the,fiscal year ...
Cached Biology Technology:Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine 2Cell Biosciences Signs Agreement to Acquire Alpha Innotech 2Cell Biosciences Signs Agreement to Acquire Alpha Innotech 3Cell Biosciences Signs Agreement to Acquire Alpha Innotech 4Cell Biosciences Signs Agreement to Acquire Alpha Innotech 5Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009 2
(Date:9/29/2014)... new study confirms that the exposure to tar tended ... of regular cigarettes. Similarly, exposure to nicotine tended ... popular type of cigarette in several countries around the ... certain toxic chemicals in the smoke of these cigarettes ... lower levels of chemicals in the smoke are not ...
(Date:9/29/2014)... Gourmet pizza in school? According to a new Food ... , chef-made meals can increase participation in the National ... and consumption of vegetables by 16%! , Chefs Move ... Move campaign, pairs chefs with schools in order to ... interested school food service workers. , A CMTS event ...
(Date:9/29/2014)... Mountain pine beetles get a bad rap, and ... pine trees over tens of millions of acres in ... , But contrary to popular belief, these pests ... like those that have recently swept through the region. ... the ecological severity of fires than these bark-boring beetles. ...
Breaking Biology News(10 mins):Slim cigarette smokers not exposed to more harmful chemicals 2Chefs move to schools can increase school meal participation and vegetable intake among students 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... human activity and the extinction of species around the ... a Canadian zoologist. This ecological damage also endangers human ... Dr. Daniel (Dan) Brooks, a parasitologist at the University ... linked to the emergence of new human and wildlife ...
... Researchers at the University of Bath have won a £261,000 ... of a designer drug that could stop influenza and some ... the grant comes at a time when fears are rising ... thousands of people. , Professor Ian Williams, of the Department ...
... “cautionary tale?about what may go wrong when using the fledgling ... , In the February 16 issue of the Journal of ... M. D. Anderson Cancer Center detail why an experimental test ... of blood is unlikely to lead to a reliable clinical ...
Cached Biology News:Ecological destruction fuels emerging diseases 2Computers to be used to find blueprint for new influenza drug 2Signaling protein builds bigger, better bones in mice 2Signaling protein builds bigger, better bones in mice 3
...
... Ribonuclease III (RNase III) from E. ... double-stranded RNA (dsRNA) to dsRNA fragments that ... dsRNA results in dsRNA fragments of 12-15 ... RNA composed of canonical ribonucleotides as well ...
...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: